Korean J Urol.  2003 Nov;44(11):1121-1123.

Erectile Response of Intracavernous Injection of New Triple Agents, Chlorpromazine, Papaverine, and Alprostadil

• Lee YS
• Kim SC

Abstract

PURPOSE: This study was aimed to compare the erectile response when phentolamine of intracavernous trimix(papaverine, phentolamine, alprostadil) was replaced with chlorpromazine.
MATERIALS AND METHODS
A total of 65 patients with erectile dysfunction(63.3+/-9.19 years of age) who had already used intracavernous injection with trimix(4.5+/-2.12 years) were recruited for this study. The erection quality and adverse reactions of chlorpromazine solution were compared with those of trimix.
RESULTS
Among 65 patients, the erection quality of the intracavernous chlorpromazine solution compared to that of trimix was worse in 26 patients(40%), better in 8(12.3%) and similar in 31(47.7%) when injected at the clinic. Among 45 patients who used the chlorpromazine solution for intracavernous self-injection at home for more than 3 months, however, the erection quality was worse in 13(28.9%), better in 8(17.8%) and similar in 24(53.3%). Intracavernous chlorpromazine solution-either injected at the clinic or self-injected-showed no significant adverse reaction.
CONCLUSIONS
Chlorpromazine could be a safe and effective substitude of phentolamine of trimix.

Keyword

Erectile dysfunction; Phentolamine; Chlorpromazine

MeSH Terms

Alprostadil*
Chlorpromazine*
Erectile Dysfunction
Humans
Male
Papaverine*
Phentolamine
Alprostadil
Chlorpromazine
Papaverine
Phentolamine